Lomitapide Mesylate Drug Asset Due Diligence Report 2026

This Lomitapide Mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lomitapide Mesylate can convert its Small molecule drug profile and MTTP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lomitapide Mesylate (query alias: lomitapide)
Modality / target	Small molecule drug; MTTP; MTTP inhibitors
Highest global status	Approved
Originator	Bristol Myers Squibb Co.
Active developers	University of Pennsylvania, CHIESI Farmaceutici SpA, Amryt Pharma Holdings Ltd.

The MCP disease footprint includes Hyperlipidemia Type IIa, Homozygous familial hypercholesterolemia, Colorectal Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04681170	Phase 3	Completed	46	Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline
EUCTR2018-002911-80-IT	Phase 3	Completed	20	Percent change in tryglicerides (TG) at the maximum tolerated dose compared to baseline after 26 weeks of treatment in combination with other lipid lowering therapy in patients with Familial Chylomicronemia Syndrome (FCS).
NCT02765841	Phase 3	Withdrawn	Not disclosed	Percent change in LDL-C

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy and safety of lomitapide in familial chylomicronaemia syndrome

Phase 3; n=18; evaluation: Positive. Reported fields: Triglycerides(vs. baseline) = -70.5 %

A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral CapsuleDose of 20 mg Lomitapide in Healthy Subjects

Phase 1; n=15; evaluation: not stated. Reported fields: Period 1(Mean) = 0.961 ng/mL (Standard Deviation, 0.556); -; -

A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia

Phase 3; n=19; evaluation: not stated. Reported fields: -; -; Percent Change in Low Density Lipoprotein Cholesterol (LDL-C)(Mean) = -45.5 Percent Change (Standard Deviation, 31.35)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lomitapide Mesylate addresses Hyperlipidemia Type IIa, Homozygous familial hypercholesterolemia, Colorectal Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 10 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-07-15	Kwangdong Pharmaceutical licenses in 4 rare disease drugs from Italy	Approved	Financial terms not disclosed
2021-02-04	Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel	Approved	Financial terms not disclosed
2019-02-06	RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN from Aegerion Pharmaceuticals Inc.	Approved	US$25.0M upfront; US$5.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “New application of compound Lomitapide in preventing or treating African swine fever”. The milestone feed surfaced a patent-application signal described as “Application of lomitapide in preparation of medicine for treating glioma”. The milestone feed surfaced a patent-application signal described as “Application of lomitapide mesylate in preparation of product for inhibiting novel coronavirus”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO